Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05485766
Other study ID # OUMK59829
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 29, 2024
Est. completion date September 30, 2027

Study information

Verified date February 2024
Source Okayama University
Contact Yuko Takahashi, MD., PhD.
Phone +81-086-223-7151
Email yukotaka@okayama-u.ac.jp
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline BRCA (gBRCA) 1/2 mutated triple negative breast cancer (TNBC). Pembrolizumab in combination with weekly paclitaxel and carboplatin (treatment 1) is followed by Pembrolizumab in combination with Olaparib (treatment 2) in neoadjuvant setting and Pembrolizumab in combination with Olaparib in adjuvant setting will be studied


Recruitment information / eligibility

Status Recruiting
Enrollment 23
Est. completion date September 30, 2027
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male/female subjects who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of invasive breast cancer - Have histologically confirmed TNBC, as defined by the most recent ASCO/CAP guidelines. - Confirmed germline BRCA 1/2 mutated. - Have previously untreated locally advanced non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per AJCC for breast cancer staging criteria version 7 as assessed by the investigator based on radiological and/or clinical assessment: 1. T1c, N1-N2 2. T2, N0-N2 3. T3, N0-N2 4. T4a-d, N0-N2 - It has been confirmed that there is no distant metastasis to each organ by the following tests. Chest: Contrast CT or FDG-PET/CT Abdominal: Contract CT* or FDG-PET/CT Bone: Bone scintigraphy or FDG-PET/CT Brain: In the case of no central nervous system symptoms, examination for brain metastasis is not required. - The subject (or legally acceptable representative if applicable) provides written informed consent for the trial. - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. - Have adequate organ function as defined in the protocol. Specimens must be collected within 10 days prior to the start of study treatment. Exclusion Criteria: - Subjects who has a positive urine pregnancy test within 72 hours prior to registration - Has diagnosed as inflammatory breast cancer. - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor . - Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention. - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. - Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. - Has severe hypersensitivity (=Grade 3) to pembrolizumab and investigational drugs used in this study and/or any of their excipients. - Has active autoimmune disease that has required systemic treatment in the past 2 years - Has a history of (non-infectious) pneumonitis/interstitial lung disease . - Has an active infection requiring systemic therapy. - Has a known history of Human Immunodeficiency Virus (HIV) infection. - Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HbsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. - Has a known history of active TB (Bacillus Tuberculosis). - Has a history or current evidence of any condition, therapy, or laboratory abnormality. - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. - Is pregnant or breastfeeding, or expecting to conceive or father children. - Has had an allogenic tissue/solid organ transplant. - Has received pre-treatment with Olaparib or other PARP inhibitors. - Has significant cardiovascular disease - Has a resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions. - Subject has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML. - Subject received colony-stimulating factors within 28 days prior to the first dose of study intervention. - Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. - Is either unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption. - Is, in the judgement of the investigator, unlikely to comply with the study procedures, restrictions, and requirements of the study. - Is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study. - Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study.

Study Design


Intervention

Drug:
Pembrolizumab
200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
Paclitaxel
80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
Carboplatin
Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
Olaparib
300 mg BID (twice daily) orally
Procedure:
Definitive Surgery
Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.

Locations

Country Name City State
Japan Aichi Cancer Center Nagoya
Japan Okayama University Hospital Okayama
Japan St. Luke's International Hospital Tokyo

Sponsors (2)

Lead Sponsor Collaborator
Okayama University Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological Complete Response (pCR) Rate (ypT0/TisypN0) Pathological complete response rate (ypT0/TisypN0) is defined as the proportion of subjects without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by AJCC staging criteria (7th edition) assessed by the local pathologist at the time of definitive surgery. From 27 weeks up to 30 weeks
Secondary Residual Cancer Burden 0/1 Residual Cancer Burden (RCB) 0/1 rate is defined as the proportion of subjects on evaluation from routine pathologic sections of the primary breast tumor and the regional lymph nodes after the completion of neoadjuvant therapy assessed by the local pathologist at the time of definitive surgery. Six variables are included in a calculation formula. The calculated RCB index value can also be categorized as one of four RCB classes (0 - 3). The calculation formula and detailed description can be found at a dedicated Web site: http://www.mdanderson.org/breastcancer_RCB. From 27 weeks up to 30 weeks
Secondary Pathological Complete Response (pCR) Rate (ypT0/is) Pathological complete response rate (ypT0/is) is defined as the proportion of subjects without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen regardless of regional lymph nodes status following completion of neoadjuvant systemic therapy by AJCC staging criteria (7th edition) assessed by the local pathologist at the time of definitive surgery. From 27 weeks up to 30 weeks
Secondary Pathological Complete Response (pCR) Rate (ypT0/Tis ypN0) Pathological complete response rate (ypT0/TisypN0) is defined as the proportion of subjects without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by AJCC staging criteria (7th edition) assessed by the local pathologist at the time of definitive surgery. From 27 weeks Up to 30 weeks
Secondary Three-Year Overall Survival (3-year OS) The Proportion of Three Year-Overall Survival (3y-OS) is defined as the proportion of survival subjects without death due to any cause at 3 years from registration. Subjects without documented death at the time of the analysis will be censored at the date of the last follow-up. Up to 3 years
Secondary Three-Year Distant Metastatic Free Survival (3-year DMFS) The Proportion of Three-Year Distant Metastatic Free Survival (3y-DMFS) is defined as the proportion of survival subjects without distant metastatic disease at 3 years from registration. Subjects without documented distant metastatic disease at the time of the analysis will be censored at the date of the last follow-up. Up to 3 years
Secondary Three-Year Disease Free Survival (3-year DFS) The Proportion of Three-Year Disease Free Survival (3y-DFS) is defined as the proportion of survival subjects without metastatic disease and secondary malignancy at 3 years from registration. Subjects without documented metastatic disease and secondary malignancy at the time of the analysis will be censored at the date of the last follow-up. Up to 3 years
Secondary AEs/SAEs and treatment discontinuation due to AEs/SAEs Safety measurements are the incidence of, causality of, and outcome of AEs/SAEs; and changes in vital sign measurements and laboratory values. Up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2